bluuebunny/crossref_metadata_2025_split huggingface dataset:
Controllable Li3PS4–Li4SnS4 solid electrolytes with affordable conductor and high conductivity for solid‐state battery
Authors: Dong Pingping , Jiao Qing , Zhang Zengcheng , Jiang Miao , Lin Changgui , Zhang Xianghua , Ma Hongli , Ma Baochen , Dai Shixun , Xu Tiefeng 
Published: December 2021

AbstractHigh ionic conductivity, low grain boundary impedance, and stable electrochemical property have become the focus for all‐solid‐state lithium–sulfur batteries (ASSLSB). One of the approaches is to promote the rapid diffusion of lithium ions by regulating the chemical bond interactions within the framework. The structure control of P5+ substitution for Sn4+ on lithium‐ion transport was explored for a series of Li3PS4–Li4SnS4 glass–ceramic electrolytes. Results showed that the grain boundary impedance of the glass electrolyte was reduced after heat treatments. The formation of LiSnPS microcrystals, a good superionic conductor, was detected by X‐ray diffraction tests. Electrochemical experiments obtained the highest conductivity of 29.5 S cm−1 at 100°C and stable electrochemical window from –0.1 to 5 V at 25°C. In addition, the cell battery was assembled with prepared electrolyte, which is promoted as a candidate solid electrolyte material with improved performance for ASSLSB.
Influence of “high” defibrillation thresholds on patient survival and impact of system modification
Authors: Siddiqi Najmul , Tchou Patrick , Niebauer Mark J. , Wilkoff Bruce L. , Varma Niraj 
Published: December 2021

AbstractObjectiveTo test whether a high defibrillation threshold (DFT) marks patients with poor outcomes which are improved when DFT is decreased by system modification (subcutaneous coil implant; SM).BackgroundThe electrical substrate generating fast ventricular arrhythmias may generate poor outcomes among patients treated with implantable cardioverter‐defibrillators (ICDs), even when arrhythmias are treated successfully. Since patients with high DFTs have increased mortality, we contrasted survival among patients with high DFT treated with and without SM.MethodsWe studied consecutive patients undergoing ICD implantation and DFT testing at Cleveland Clinic over a 14‐year period. High DFT was defined as successful defibrillation by shock strength >25 J or ≤10 J of maximal device output. Mortality was recorded using the Social Security Death Index. Survival was compared among those high DFT patients receiving SM versus the remainder.ResultsOut of 6353 patients tested, 191 (3%) had high DFT (32.1 ± 3.7 J) versus 13.9 ± 4.9 J in the remainder (“acceptable DFT,” p < .001). One hundred twenty‐one high DFT patients (63%; 33.3 ± 3.4 J) underwent SM, which significantly decreased DFT (24.8 ± 5.9 J; p < .001). Seventy patients (37%; 30.3 ± 3.3 J) did not undergo SM. During follow‐up, 38% (2363/6162; 7.8 yrs) patients with acceptable DFT died versus 48% high DFT patients (91/191; 5.6 yrs.; p < .001). Concomitantly, 48% patients with SM (58/121) died, as compared to 47% patients (33/70) without SM (p = .91); median follow‐up 4.9 yrs).ConclusionPatients with high DFT have a higher mortality than those with acceptable DFT. The additional subcutaneous coil implant decreases DFT to an acceptable range but does not appear to improve survival. The electrical substrate underlying high DFT appears to determine survival.
A tale of two multi‐focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone‐based OKN‐007
Authors: Zalles Michelle , Smith Nataliya , Saunders Debra , Lerner Megan , Fung Kar‐Ming , Battiste James , Towner Rheal A. 
Published: December 2021

AbstractGlioblastoma (GBM) is the most common primary malignant brain tumour in adults. Despite a multimodal treatment response, survival for GBM patients remains between 12 and 15 months. Anti‐ELTD1 antibody therapy is effective in decreasing tumour volumes and increasing animal survival in an orthotopic GBM xenograft. OKN‐007 is a promising chemotherapeutic agent that is effective in various GBM animal models and is currently in two clinical trials. In this study, we sought to compare anti‐ELTD1 and OKN‐007 therapies, as single agents and combined, against bevacizumab, a commonly used therapeutic agent against GBM, in a human G55 xenograft mouse model. MRI was used to monitor tumour growth, and immunohistochemistry (IHC) was used to assess tumour markers for angiogenesis, cell migration and proliferation in the various treatment groups. OKN and anti‐ELTD1 treatments significantly increased animal survival, reduced tumour volumes and normalized the vasculature. Additionally, anti‐ELTD1 was also shown to significantly affect other pro‐angiogenic factors such as Notch1 and VEGFR2. Unlike bevacizumab, anti‐ELTD1 and OKN treatments did not induce a pro‐migratory phenotype within the tumours. Anti‐ELTD1 treatment was shown to be as effective as OKN therapy. Both OKN and anti‐ELTD1 therapies show promise as potential single‐agent multi‐focal therapies for GBM patients.
The loss of molars in supportive periodontal care: A 10‐year follow‐up for tooth‐ and patient‐related factors
Authors: Costa Fernando Oliveira , Cortelli José Roberto , Cortelli Sheila Cavalca , Costa Amanda Almeida , Esteves Lima Rafael Paschoal , Costa Adriana Moreira , Pereira Gustavo Henrique Mattos , Cota Luís Otávio Miranda 
Published: December 2021

AbstractAimTo determine the impact of the degree of furcation involvement (FI) on the longevity of molar teeth and assess the risk variables (tooth‐ and patient‐related factors) associated with the loss of molars (LM) in individuals treated for periodontitis and monitored in a private programme of supportive periodontal care (SPC).Materials and MethodsThe present retrospective cohort study included 222 individuals with 1329 molars under a 10‐year monitoring period in SPC. Periodontal clinical parameters, FI, the type of molar, pulp vitality, and other variables of interest were collected at approximately 50 days after active periodontal therapy and after 10 years. The association of tooth‐ and patient‐related factors with LM was assessed using a multilevel Cox regression analysis.ResultsTwo‐hundred and thirty‐five molars were extracted during the SPC period of 12.4 ± 1.9 years. Age >50 years, male gender, diabetes, smoking, and non‐compliance were identified as relevant patient‐related factors for LM during SPC (p < .05). Significant tooth‐related factors for LM were bleeding on probing (BoP) and probing depth (PD) ≥5 mm, tooth non‐vitality, and class II and III FI (p < .05).ConclusionsClass III FI, tooth non‐vitality, higher mean PD and BoP, age, male gender, diabetes, and smoking all strongly influenced the prognosis of molars during SPC.
Activation of p38 mitogen‐activated protein kinase pathway by lipopolysaccharide aggravates postoperative ileus in colorectal cancer patients
Authors: Liu Lujia , Liu Yang , Guo Xiao , Jin Xiangren , Yan Wei , Lin Baiqiang , Cai Ting , Wei Yunwei 
Published: December 2021

AbstractBackground and AimPatients undergoing abdominal surgery can develop postoperative ileus (POI). Inflammation of the intestinal muscularis following intestinal manipulation may be caused by displaced bacteria or lipopolysaccharide (LPS). The aim of this study was to investigate the relationship between gut microbiota, LPS, and POI in colorectal cancer (CRC) patients and explore underlying mechanisms of LPS‐triggered POI.MethodsSixty CRC patients undergoing colorectal resection were included. Bacterial communities from fecal samples were characterized by 16S rRNA gene sequencing, and fecal LPS levels were determined by Limulus amebocyte lysate assay. Mice were used to mechanistically investigate the causal relationship between microbiota, LPS, and POI.ResultsWe discovered that CRC patients who developed prolonged POI (PPOI) had a unique pro‐inflammatory gut microbial composition during the perioperative period. The highest proportions of Gram‐negative bacteria at the genus level were Escherichia–Shigella and Bacteroides; the abundance of Escherichia–Shigella was higher throughout the perioperative period. Fecal LPS levels were significantly higher in patients with PPOI. In mice treated with an antibiotic cocktail, intestinal muscularis inflammation and intestinal dysfunction were significantly improved. Inflammation and dysfunction were significantly reduced in mice treated with polymyxin B, but were worsened by treatment with LPS. Moreover, LPS upregulated p38 phosphorylation in mice, and treatment with an inhibitor of p38 (SB203580) significantly alleviated intestinal inflammation and dysmotility.ConclusionLipopolysaccharide increases intestinal muscularis inflammation via activation of p38 signaling, which aggravates POI. Removing bacterial sources of LPS during the perioperative period is promising for the prophylactic treatment of PPOI.
Effect of remimazolam tosilate on early cognitive function in elderly patients undergoing upper gastrointestinal endoscopy
Authors: Tan Yingjie , Ouyang Wen , Tang Yongzhong , Fang Ning , Fang Chao , Quan Chengxuan 
Published: December 2021

AbstractBackground and AimRemimazolam tosilate (RT) is under evaluation as a sedative for endoscopic procedures. Herein, we aimed to evaluate safety including cognition recovery of RT administered in elderly patients undergoing upper gastrointestinal endoscopy and assess its safety dosage.MethodsNinety‐nine patients presenting for upper gastrointestinal endoscopy were randomized to receive 0.1 mg/kg RT (R1) or 0.2 mg/kg RT (R2), or propofol (P). Cognitive functions (memory, attention, and executive function) were measured via neuropsychological tests conducted before sedation and 5 min after recovery to full alertness. Adverse events were also assessed.ResultsThere were no statistical differences between postoperative and baseline results for R1 group and P group, whereas those for R2 group revealed worsened postoperative cognitive functions (immediate recall and short delay recall) than baseline (P < 0.05). Compared with P group, Scores demonstrated worse restoration of immediate recall in R1 group, immediate recall, short‐delayed recall, and attention function in R2 group (P < 0.05). Patients in R2 group had a longer sedation time (12.09 vs 8.27 vs 8.21 min; P < 0.001) and recovery time (6.85 vs 3.82 vs 4.33 min; P < 0.001) than that in R1 group and P group. Moreover, the incidence of hypotension was 3.0% in R1 group, whereas it was 21.2% in R2 group and 48.5% in P group (P < 0.05).ConclusionThe addition of 0.1 mg/kg RT as an adjunct to opiate sedation for upper gastrointestinal endoscopy not only achieves more stable perioperative hemodynamics but also achieves acceptable neuropsychiatric functions in elderly patients.
Interaction between CETP Taq1B polymorphism and HEI, DQI and DPI on metabolic biomarkers in patients with type 2 diabetes
Authors: Kalantar Zahra , Sotoudeh Gity , Esmaeily Zahra , Rafiee Masoumeh , Koohdani Fariba 
Published: December 2021

AbstractBackgroundType 2 diabetes mellitus (T2DM) is a multidimensional consequence of environmental and genetic factors. Cholesteryl ester transfer protein (CETP) Taq1B polymorphism has been reported as a main predictor of dyslipidaemia, comprising an important complication in persons with T2DM. However, diet could affect T2DM patients metabolic health.MethodsWe investigated the combination of gene–diet effects on some metabolic biomarkers. In our cross‐sectional study, blood samples of 220 patients were collected. Dietary indices (healthy eating index, dietary quality index and dietary phytochemical index) were obtained from a validated semi‐quantitative food frequency questionnaire. CETP Taq1B polymorphism was genotyped by a polymerase chain reaction‐restriction fragment polymorphism method. Data were analysed by analysis of covariance.ResultsThe interaction between the CETP Taq1B polymorphism and dietary indices on low density lipoprotein/high density lipoprotein was significant (p < 0.001 both crude and adjusted models). In addition, the interaction between polymorphism and dietary quality index on total antioxidant capacity (p = 0.004 crude model, p = 0.005 after adjusting) and pentraxin 3 (p = 0.01 both crude and adjusted models) was significant. Also, the interaction between polymorphism and healthy eating index on waist circumference (p = 0.005 both crude and adjusted models) and dietary phytochemical index on interleukin‐18 (p = 0.03 crude model) was significant.ConclusionsOur results indicated the effect of CETP Taq1B polymorphism on some inflammatory and anthropometrics markers (total antioxidant capacity, pentraxin 3, interleukin‐18, low density lipoprotein/high density lipoprotein and waist circumference) with high and low adherence to dietary incides.
Role of the rs10401670 variant in the resistin gene on the metabolic response after weight loss secondary to a high‐fat hypocaloric diet with a Mediterranean pattern
Authors: de Luis Daniel , Aller Rocío , Izaola Olatz , Primo David 
Published: December 2021

AbstractBackgroundThe single nucleotide polymorphism (SNP) (rs10401670) of the RETN gene has been associated with metabolic disorder in obese subjects and has scarcely been evaluated after dietary interventions. The present study aimed to analyse the effects of the rs10401670 RETN gene polymorphism on metabolic changes secondary to weight loss and secondary to a high‐fat hypocaloric diet with a Mediterranean dietary pattern.MethodsA Caucasian population comprising 284 obese patients without diabetes mellitus was analysed. Before and after 3 months of a high‐fat hypocaloric diet with a Mediterranean pattern, an anthropometric evaluation, an assessment of nutritional intake and a biochemical analysis were performed. A statistical analysis was conducted for the combined CT and TT as a group and for wild‐type CC as a second group.ResultsDecreases in weight, body mass index (BMI), fat mass, systolic blood pressure and waist circumference were similar in both genotypes groups. In T allele carriers, insulin, homeostatic model assessment for insulin resistance (HOMA‐IR), triglycerides and C‐reactive protein levels were decreased. The decrease in these parameters was statistically significant for triglycerides (−22.3 ± 9.3 mg dl–1: p = 0.03), C‐reactive protein (−2.8 ± 0.5 mg dl–1: p = 0.03), insulin (−7.4 ± 2.9 mUI L–1: p = 0.03) and HOMA‐IR (−2.4 ± 1.0: p = 0.02). Leptin levels were decreased in both genotypes groups after the hypocaloric diet, as well as the anthropometric parameters BMI, weight, waist circumference and fat mass. Resistin and adiponectin levels remained unchanged in both groups.ConclusionsIn the present study, we have detected a significant association between the T allele of this SNP and a better response of insulin resistance, triglycerides and C‐reactive protein compared to non T allele carriers after weight loss with a high‐fat hypocaloric diet and a Mediterranean diet.
Impact of patient characteristics on clinicians' decisions to involve dietitians in eating disorder treatment
Authors: McMaster Caitlin M. , Wade Tracey , Franklin Janet , Waller Glenn , Hart Susan 
Published: December 2021

AbstractBackgroundDietetic involvement in eating disorder (ED) treatment is often initiated by other members of a patient's treating team. The present study aimed to examine the impact of patient characteristics on clinicians' decisions to involve a dietitian in a patient's ED treatment, as well as the influence of clinician characteristics on their decision‐making.MethodsED clinicians were recruited to complete an online survey, which used case vignettes to assess their likelihood of referring patients to a dietitian or consulting with a dietitian for guidance. Questions were also included that measured clinician anxiety, beliefs about the therapy they deliver, beliefs about dietitians and views on evidence‐based practice to determine whether these were related to their responses to case vignettes.ResultsFifty‐seven clinicians completed the survey, with the largest group being clinical psychologists (n = 22, 39%). ED diagnosis, weight status, medical co‐morbidities and progress in treatment were all shown to be influential on whether clinicians involved dietitians in ED treatment. Clinician characteristics and their beliefs about dietitians were generally not correlated with the likelihood of seeking dietetic input.ConclusionsThe present study indicates that clinicians' decisions to involve dietitians in ED treatment are systematic rather than random decisions influenced by individual clinician characteristics. Clinicians require further education on the potential for malnutrition regardless of patients' ED diagnosis or weight status, and the dietitian's role in addressing this.
The effect of a dual‐wavelength 532 nm and 1064 nm picosecond‐domain laser with a fractionated holographic optic on photoaging and patient age perception: A pilot study
Authors: Leight‐Dunn Hayley , Hadi Ali , Patel Forum , Yao Christopher J. , Tu Yingqi Michelle , Chapas Anne 
Published: December 2021

AbstractIntroductionThis study evaluated the efficacy of a dual‐wavelength 532 nm/1064 nm Nd:YAG picosecond‐domain laser with a holographic lens array in treating facial photoaging.MethodsThirteen subjects were enrolled with 10 completing the study. Receiving three‐month treatments, subjects underwent full‐face spot treatment of facial lentigines with the 532‐nm non‐fractionated handpiece, followed by two sequential facial passes of the 1064‐nm and the 532‐nm fractionated handpieces. Improvement was measured by treating physician evaluation of pigmentation and rhytids as well as blinded reviewer evaluation of pre‐ and post‐treatment image sets taken 12 weeks after the final treatment. Participants completed treatment surveys to assess satisfaction.ResultsPhysician grading on a 5‐point scale revealed an average improvement of 1.6 in pigmentation (p = 0.0042) and 0.9 in rhytids (p = 0.0196). Blinded physicians appropriately selected baseline images in 44 of 50 (88%) image sets (10 subjects; five reviewers). On an 11‐point scale for overall facial photoaging (0 = no change, 1 = 10% improvement, 2 = 20% improvement, etc.) treating physicians scored mean improvement as 3.3 ± 1.83 (95% CI 1.99 to 4.61; range 1–6), while blinded reviewers scored mean improvement as 2.32 ± 2.62 (range % −4 to 8, 95% CI 1.57 to 3.07). The greatest majority (80%) of participants reported satisfaction with the treatment. Adverse events were mild; however, one patient developed hyperpigmentation, consistent with melasma that was successfully treated with topical agents.ConclusionThis is the first study to show that picosecond‐domain 532 nm/1064 nm laser treatments with combination non‐fractionated and fractionated handpieces are well‐tolerated, safe, and effective for the treatment of photodamage.
Androgenetic alopecia and COVID‐19: Is there a clinical connection?
Authors: Baghani Moein , Pourani Mohammad Reza , Nekooghadam Sayyed Mojtaba , Ommi Davood , Fatemi Alireza , Abdollahimajd Fahimeh , Moravvej Hamideh 
Published: December 2021

AbstractBackgroundDuring the coronavirus disease 2019 (COVID‐19) outbreak, multiple studies showed higher rates of severe infection in adults and specifically in male patients, which may be related to differences in androgen receptor (AR) expression. Androgenetic alopecia (AGA) is one of the AR expression manifestations.AimTo explore AGA severity as a possible risk factor for COVID‐19 severity in hospitalized patients.MethodsA total of 164 subjects (116 men and 48 females) with confirmed COVID‐19 in need of hospitalization were included in this study. An experienced dermatologist examined the correlation of clinical signs of COVID‐19 severity with AGA types. For evaluation of the association between categorical variables and comparison of the mean age in three groups of COVID‐19 patients, the Fisher's exact test and the analysis of variance were used.ResultsOur cross‐sectional study included 116 male patients (70.7%) with a median age of 65.5 (age range: 22–97) years. Among them, 13.8% required intubation, 15.5% needed intensive care unit (ICU) care, and 70.7% required inward hospitalization. The Hamilton–Norwood Scale (HNS) was as follows: HNS I 14.7%, HNS II 12.1%, HNS III 20.7%, HNS IV 19.8%, HNS IV 29.8%, HNS V 17.2%, HNS VI 13.8%, and HNS VII 1.7%. Also, 29.3% of the patients were female, possessing a median age of 72 (age range: 23–98) years. In this group, 8.3% required intubation, 6.3% required ICU care, and 85.4% needed inpatient ward admission care. The Ludwig Scale (LS) was as follows: LS I 52.1%, LS II 35.4%, and LS III 12.5%.ConclusionThe severity of AGA type did not correlate with the severity of COVID‐19 among hospitalized patients. Our results were in contrast with other research that suggested AGA severity as a marker of unfavorable outcomes of COVID‐19.
Efficacy and safety of a novel mucoadhesive clobetasol patch for treatment of erosive oral lichen planus: A phase 2 randomized clinical trial
Authors: Brennan Michael T. , Madsen Lars Siim , Saunders Deborah P. , Napenas Joel J. , McCreary Christine , Ni Riordain Richeal , Pedersen Anne Marie Lynge , Fedele Stefano , Cook Richard J. , Abdelsayed Rafik , Llopiz Maria T. , Sankar Vidya , Ryan Kevin , Culton Donna A. , Akhlef Yousra , Castillo Fausto , Fernandez Inti , Jurge Sabine , Kerr Alexander R. , McDuffie Chad , McGaw Tim , Mighell Alan , Sollecito Thomas P. , Schlieve Thomas , Carrozzo Marco , Papas Athena , Bengtsson Thomas , Al‐Hashimi Ibtisam , Burke Laurie , Burkhart Nancy W. , Culshaw Shauna , Desai Bhavik , Hansen Jens , Jensen Pia , Menné Torkil , Patel Paras B. , Thornhill Martin , Treister Nathaniel , Ruzicka Thomas 
Published: December 2021

AbstractBackgroundOral lichen planus (OLP) is a chronic inflammatory disorder of the oral mucosa. Currently there is no approved treatment for OLP. We report on the efficacy and safety of a novel mucoadhesive clobetasol patch (Rivelin®‐CLO) for the treatment of OLP.MethodsPatients with confirmed OLP and measurable symptomatic ulcer(s) participated in a randomized, double‐blind, placebo‐controlled, multicenter clinical trial testing a novel mucoadhesive clobetasol patch (Rivelin®‐CLO) in OLP across Europe, Canada, and the United States. Patients were randomized to placebo (nonmedicated), 1, 5, 20 µg Clobetasol/patch, twice daily, for 4 weeks. The primary endpoint was change in total ulcer area compared to baseline. Secondary endpoints included improvement from baseline in pain, disease activity, and quality of life.ResultsData were analyzed and expressed as mean [SD]. One hundred thirty‐eight patients were included in the study; 99 females and 39 males, mean age was 61.1 [11.6] years. Statistical analyses revealed that treatment with 20‐μg Rivelin®‐CLO patches demonstrated significant improvement with ulcer area (p = 0.047), symptom severity (p = 0.001), disease activity (p = 0.022), pain (p = 0.012), and quality of life (p = 0.003) as compared with placebo. Improvement in OLP symptoms from beginning to the end of the study was reported as very much better (best rating) in the 20‐µg group (25/32) patients compared to the placebo group (11/30), (p = 0.012). Adverse events were mild/moderate. Candidiasis incidence was low (2%).ConclusionsRivelin®‐CLO patches were superior to placebo demonstrating statistically significant, clinically relevant efficacy in objective and subjective improvement and, with a favorable safety profile.